TGFB1 and breast cancer: EVs released from treatment-resistant variants of HER2+ BC contained high levels of the immunosuppressive cytokine TGF-β1 and increased PD-L1, and were resistant to HER2 antibody trastuzumab-mediated cytotoxicity [73].